Age-Related Macular Degeneration: Causes, Symptoms, Diagnosis, and Treatment

What is Macular Degeneration?

Macular degeneration, most commonly referred to as age-related macular degeneration (AMD), is a chronic, progressive retinal disease affecting the macula, the small but critically important central region of the retina. Because it predominantly affects individuals over the age of 60, it is also widely known as senile macular degeneration.

AMD is the leading cause of severe, irreversible visual impairment and blindness in adults over 65 in the developed world. It is estimated to affect more than 200 million people globally, a number expected to double by 2040 as the world’s population ages. Unlike many other eye conditions that can be corrected with glasses or surgery, AMD selectively destroys central vision, the precise and detailed sight essential for reading, recognizing faces, driving, and performing most daily tasks, while leaving peripheral (side) vision largely intact.

Despite its prevalence and devastating impact on quality of life, AMD remains a condition that is incompletely understood, incompletely treatable, and underdiagnosed. Many people, particularly older adults, accept progressive vision deterioration as an inevitable consequence of aging rather than seeking timely medical evaluation that might reveal a treatable disease.

How the Eye Works: A Brief Overview

To appreciate why AMD has such a profound and specific impact on vision, it is helpful to briefly understand the fundamental anatomy and physiology of the human eye.

The eye functions essentially as a sophisticated biological camera, capturing light from the environment, focusing it precisely onto a photosensitive surface, and converting the optical signal into electrical impulses that the brain can interpret as visual images.

Three principal structural components collaborate to achieve this:

1. The Cornea and Lens

The cornea (the transparent outer surface of the eye) and the crystalline lens (located just behind the pupil) constitute the eye’s optical focusing system. Working together, they bend and concentrate incoming light rays to form a sharp, inverted image on the retina at the back of the eye. The lens is flexible; it changes shape (a process called accommodation) to adjust the focus for objects at different distances. This is guided by the ciliary muscles that surround it.

2. The Retina and the Macula

The retina is a thin, multilayered sheet of neural tissue lining the inner back surface of the eye, roughly analogous to the film in a traditional camera (or the image sensor in a digital camera). It is composed of millions of specialized photoreceptor cells, namely the rods and cones, which are sensitive to light of different wavelengths and intensities:

• Rods: Responsible for vision in low-light conditions (scotopic vision) and for detecting motion; they are distributed throughout the peripheral retina
• Cones: Responsible for color vision and fine detail discrimination (photopic vision). They are concentrated in the central retina, particularly in the macula.

The macula is a small, oval-shaped region of the retina, approximately 5.5 mm in diameter. It is located at the posterior pole of the eye, directly in line with the visual axis. Within the macula lies the fovea, an even smaller central pit (approximately 1.5 mm in diameter) containing the highest concentration of cone photoreceptors in the entire retina. The fovea is responsible for the exquisite central visual acuity that enables us to read fine print, recognize faces, thread a needle, and perform any task requiring precision vision.

Immediately beneath the photoreceptor layer of the retina lies the retinal pigment epithelium (RPE), a single layer of pigmented cells that performs critical supportive functions for the photoreceptors, including:

• Transporting nutrients from the underlying choroidal blood supply to the photoreceptors
• Phagocytosing and recycling shed photoreceptor outer segments
• Maintaining the blood-retinal barrier
• Absorbing stray light to improve image clarity

Beneath the RPE lies the Bruch’s membrane, a layered extracellular matrix structure, and then the choroid, the richly vascularized layer of tissue that provides the primary blood supply to the outer retina and RPE.

In AMD, it is precisely the complex relationship between the RPE, Bruch’s membrane, and the choroidal circulation that breaks down, leading to progressive photoreceptor dysfunction and death in the macula.

Because the peripheral retina, which is responsible for peripheral (side) vision and motion detection, remains relatively unaffected in AMD, patients retain peripheral vision even as central vision is progressively destroyed. This is an important and somewhat counterintuitive feature: a person with advanced AMD may be unable to read a word or recognize a face directly in front of them, yet can navigate a room and detect movement in their peripheral vision.

3. The Optic Nerve

The optic nerve, which comprises approximately one million nerve fiber axons, transmits the electrical signals generated by the retinal photoreceptors and processed by the retinal ganglion cells to the brain’s visual processing centers (the lateral geniculate nucleus and primary visual cortex). In AMD, the optic nerve itself is not directly affected; the primary pathology is in the retina.

---

Classification

Age-related macular degeneration encompasses two clinically, pathophysiologically, and prognostically distinct forms that share the same ultimate anatomical target but differ fundamentally in their mechanism, rate of progression, and therapeutic responsiveness:

Dry (Atrophic) AMD: The More Common Form

Dry AMD (also called non-neovascular or atrophic AMD) accounts for approximately 85–90% of all AMD cases and represents the earlier and less acutely severe form of the disease.

Its defining pathological features are:

• Drusen: The earliest hallmark of AMD, these are small, yellowish deposits of cellular waste products and lipid-rich material that accumulate between the RPE and Bruch’s membrane. Drusen are classified by size (small, medium, and large) and morphology (hard or soft). Large, soft, confluent drusen are associated with significantly higher risk of progression to advanced AMD. On fundoscopic examination, drusen appear as yellowish-white spots scattered in the macular region.

• RPE changes: Abnormal hyperpigmentation or hypopigmentation of the RPE (visible as pigment clumping or depigmented patches) reflects metabolic stress and early cell dysfunction.

• Geographic atrophy: In advanced dry AMD, the RPE undergoes progressive apoptotic cell death. The atrophied areas expand slowly and coalesce, creating characteristic map-like (areolar) patches of RPE loss visible on fundoscopic examination. As the RPE atrophies, the overlying photoreceptors that it supports also die, resulting in corresponding areas of irreversible central visual field loss.

Dry AMD typically progresses very slowly over years to decades and causes gradual, progressive central vision loss rather than the sudden, dramatic deterioration characteristic of wet AMD. However, approximately 10–15% of patients with dry AMD will eventually convert to wet AMD, which is responsible for the majority of severe vision loss in AMD.

There is currently no approved pharmacological treatment capable of halting or reversing established geographic atrophy in dry AMD, though several promising therapeutic candidates are in late-stage clinical development. Preventive strategies (nutritional supplementation, lifestyle modification) can slow progression in patients with intermediate or advanced dry AMD in one eye.

Wet (Exudative or Neovascular) AMD: The More Severe Form

Wet AMD (also called neovascular or exudative AMD) accounts for approximately 10–15% of AMD cases but is responsible for the majority of severe and rapid vision loss associated with the disease.

Its defining pathological event is choroidal neovascularization (CNV), the abnormal growth of new blood vessels from the choroid through Bruch’s membrane and beneath (or through) the RPE. This is stimulated by the upregulation of vascular endothelial growth factor (VEGF) in the hypoxic, metabolically stressed macular tissue.

These newly formed blood vessels (the neovascular membrane) are pathologically abnormal: they have thin, fragile walls that are permeable to plasma proteins and blood.

• Fluid exudation: Plasma components leak from the abnormal vessels, accumulating beneath the RPE (sub-RPE fluid), between the RPE and the neurosensory retina (subretinal fluid), or within the retinal layers themselves (intraretinal fluid). This fluid accumulation causes the retinal layers to separate, distorts the photoreceptors, and impairs visual function.
• Serous or hemorrhagic RPE detachment: Accumulated fluid can cause the RPE to lift away from Bruch’s membrane, a condition called pigment epithelial detachment (PED).
• Subretinal hemorrhage: The fragile neovascular vessels can rupture spontaneously, causing sudden subretinal bleeding that rapidly and dramatically destroys photoreceptors.
• Disciform scar: The repeated cycle of hemorrhage and fibrovascular repair ultimately results in the formation of a dense fibrous scar beneath the retina, known as the disciform scar, representing the end-stage of wet AMD. Once a disciform scar has formed in the fovea, central vision in that region is permanently and irreversibly lost.

Wet AMD causes rapid and severe central vision loss, sometimes developing over days to weeks, in stark contrast to the slow progression of dry AMD. However, unlike the dry form, wet AMD has an effective, evidence-based treatment: anti-VEGF therapy (see Treatment section).

Juvenile Macular Degeneration and Stargardt Disease

It is important to note that macular degeneration is not exclusively a disease of the elderly. Juvenile macular degeneration, which is typically inherited and presents in children, adolescents, or young adults, encompasses a distinct group of genetic disorders called macular dystrophies.

The most important of these is Stargardt disease, the most common inherited macular dystrophy. In most cases, it is caused by mutations in the ABCA4 gene and is inherited in an autosomal recessive pattern. Stargardt disease is characterized by:

• Onset typically in the first or second decade of life
• Characteristic yellowish-white pisciform (fish-shaped) or oval flecks surrounding the central macular RPE
• Severe, progressive reduction in visual acuity (often to 20/200 or worse)
• The presence of a lipofuscin-like material (A2E) accumulating in the RPE due to the defective ABCA4 transporter
• Fundoscopic and autofluorescence imaging features that are diagnostically distinctive

Stargardt disease is genetically, pathophysiologically, and clinically distinct from age-related AMD, though both involve progressive macular photoreceptor loss.

---

Causes and Risk Factors

The precise etiology of AMD remains incompletely understood, despite decades of intensive research. It is now recognized as a complex, multifactorial disease driven by the interplay of genetic predisposition, aging-related cellular and molecular changes, and environmental exposures. No single cause has been identified. Instead, AMD results from the convergence of multiple contributing factors that collectively overwhelm the retina’s capacity for maintenance and repair.

Pathophysiological Mechanisms

At the cellular and molecular level, the pathogenesis of AMD involves several interrelated processes:

• Oxidative stress: The retina, and particularly the macula, is one of the most metabolically active tissues in the human body, with extremely high oxygen consumption. This metabolic intensity generates reactive oxygen species (ROS) that damage cellular components, particularly the polyunsaturated fatty acids (PUFAs) that are abundant in photoreceptor outer segment membranes. Over decades, this cumulative oxidative damage to the RPE cells impairs their ability to perform their essential supportive and phagocytic functions.

• Drusen formation and complement activation: Drusen, the hallmark early deposits of AMD, contain numerous inflammatory molecules, including components of the complement system. Genetic variants in complement pathway genes, particularly CFH (see below), strongly predispose to AMD. Complement-mediated chronic low-grade inflammation in the macular RPE and Bruch’s membrane is now considered central to AMD pathogenesis.

• Bruch’s membrane changes: With aging, Bruch’s membrane becomes thicker, less elastic, and more lipid-rich. These changes impair the diffusion of nutrients and waste products between the choroid and the RPE, compromising RPE metabolic function.

• VEGF upregulation and neovascularization: In wet AMD, the hypoxic, VEGF-rich microenvironment of the diseased macular tissue drives the formation of the pathological choroidal neovascular membrane.

Identified Risk Factors

Non-Modifiable Risk Factors

• Age: The single strongest risk factor for AMD. The prevalence of AMD increases dramatically with advancing age, from approximately 2% at age 50–59 to 30% or more in individuals aged 75 and older. The risk roughly doubles with each decade of life after 50.

• Male sex: Men have a modestly higher risk of developing AMD compared to women of the same age, though the reasons for this sex difference are not fully elucidated.

• Genetic factors: AMD has a strong hereditary component. The most important identified genetic risk factors are:

  • CFH gene (Complement Factor H): The single nucleotide polymorphism rs1061170 (Y402H variant) in the CFH gene, which encodes a key regulator of the complement pathway, is associated with an approximately fivefold increased risk of AMD. CFH normally suppresses complement activation in the retina; the risk variant reduces this regulatory function, allowing unchecked complement-mediated inflammation.
  • ARMS2 gene (Age-Related Maculopathy Susceptibility 2): Variants in ARMS2 are also strongly associated with AMD risk, though the functional mechanism remains less well-defined than for CFH.
  • Additional risk variants have been identified in genes encoding complement components (C3, CFB, CFI), VEGF pathway components, and lipid metabolism genes.
  • Family history: Having a first-degree relative (parent or sibling) with AMD significantly increases an individual’s risk.

• Race/ethnicity: AMD predominantly affects people of European (White/Caucasian) ancestry. It is less common in African, Hispanic, and Asian populations, though it does occur in all ethnic groups.

Modifiable Risk Factors

• Cigarette smoking: The most powerful modifiable risk factor for AMD, current smokers have two to four times the risk of developing AMD compared to non-smokers. The risk remains elevated for years after quitting, though it gradually declines. Smoking promotes oxidative damage, reduces antioxidant defenses, causes choroidal ischemia, and promotes inflammatory changes in the RPE.

• Alcohol abuse: Heavy alcohol consumption is associated with increased AMD risk, likely through oxidative stress mechanisms and impaired antioxidant status.

• Diabetes mellitus: Chronic hyperglycemia accelerates microvascular damage throughout the body, including the choroidal and retinal circulation. Diabetic patients have significantly higher rates of AMD and accelerated disease progression.

• Sedentary lifestyle: Physical inactivity is associated with multiple cardiometabolic risk factors (obesity, hypertension, diabetes) that collectively impair the microvascular health of the choroid and retina. Regular physical activity has been associated with reduced AMD risk in several epidemiological studies.

• Diet poor in vitamins and antioxidants: A diet low in antioxidant vitamins (C, E), carotenoids (such as lutein and zeaxanthin, the primary macular pigment components), zinc, and omega-3 fatty acids (particularly DHA and EPA, found in fish oil) is associated with higher AMD risk. Conversely, high dietary intake of these nutrients is associated with lower risk and slower disease progression.

• Hypertension: Elevated blood pressure impairs choroidal blood flow and promotes microvascular damage. Hypertension is an independent risk factor for both AMD incidence and progression.

• Coagulation disorders: Abnormalities of the coagulation system can impair the microcirculation of the choroid, potentially contributing to AMD risk.

• Prolonged exposure to intense light sources: Chronic exposure to bright light, particularly high-energy blue and ultraviolet wavelengths, generates photochemical damage to the RPE and photoreceptors. Long-term unprotected exposure to sunlight and artificial high-intensity light sources is associated with increased AMD risk.

• Obesity: Elevated body mass index (BMI) is associated with increased AMD risk, likely through its association with systemic inflammation, vascular risk factors, and altered antioxidant and lipid metabolism.

---

Symptoms

The clinical presentation of AMD is highly variable and depends critically on:

• The form of the disease (dry vs. wet)
• The stage of disease (early, intermediate, or advanced)
• Whether one or both eyes are affected

A particularly important clinical consideration is that AMD can be significantly underestimated in severity when only one eye is affected. Because the brain automatically suppresses input from the worse-seeing eye and relies on the fellow eye, patients with unilateral advanced AMD may not notice any visual difficulty in daily life until the second eye is also affected or until they accidentally cover the “good” eye.

Symptoms of Dry (Atrophic) AMD

The onset of dry AMD is typically insidious and gradual, developing over months to years:

• Blurred central vision: One of the earliest and most characteristic symptoms is that the center of the visual field appears less sharp and clear than it previously did. Fine print becomes difficult to read; facial features become harder to distinguish; objects appear slightly out of focus even with optimal spectacle correction.

• Central scotoma (blind spot): As geographic atrophy expands in the macula, a central blind spot develops that progressively enlarges over time, eventually making reading, face recognition, and other central vision tasks impossible. Patients may describe a persistent gray, dark, or empty patch in the center of their vision.

• Metamorphopsia: A distortion of straight lines and objects, which appear wavy, bent, or irregular. This is particularly noticeable when looking at straight lines such as window frames, doorways, or printed text. Metamorphopsia is tested clinically using the Amsler grid, a grid of fine squares that a patient views with each eye separately. Distortion, waviness, or missing areas of the grid suggest AMD or other macular pathology.

• Difficulty reading: Progressive difficulty reading fine print, even with adequate lighting and appropriate reading glasses. Reading becomes slow, effortful, and eventually impossible without magnification aids.

• Difficulty seeing in bright light (photophobia and glare): Increased sensitivity to glare and difficulty seeing in brightly lit environments. This is a somewhat paradoxical symptom caused by dysfunction of the cone photoreceptors, which normally operate optimally in bright conditions.

• Impaired dark adaptation: Difficulty transitioning from bright to dim environments. The process of adapting to lower light levels becomes slower and less complete. Patients may report difficulty seeing in restaurants or cinemas after entering from brightly lit outdoor environments.

• Difficulty distinguishing faces and fine details: Progressive inability to recognize faces, even familiar ones, or to perceive the fine details of images, text, or visual scenes.

Symptoms of Wet (Neovascular) AMD

Wet AMD typically presents with sudden, rapid, and severe visual symptoms, often developing over days to weeks:

• Sudden central vision loss: A dramatic and alarming sudden deterioration of central vision. The patient may wake up one morning and find their central vision severely blurred, distorted, or absent. This reflects the acute impact of subretinal fluid accumulation, hemorrhage, or rapid CNV expansion on foveal photoreceptors.

• Severe metamorphopsia: Marked distortion of straight lines and objects, typically more severe and sudden in onset than in dry AMD.

• Perception of a central shadow or scotoma: A central dark, gray, or blurry area that obscures the center of the visual field.

Any sudden change in vision in a patient with known AMD, or in any adult over 60, must be considered a medical emergency until proven otherwise and warrants urgent ophthalmological evaluation within 24–48 hours.

Symptoms Common to Both Forms

• Reduced visual acuity: A measurable reduction in best-corrected visual acuity on Snellen chart testing.
• Color perception changes: Colors may appear less vivid or saturated than before, reflecting cone photoreceptor dysfunction.
• Bilateral disease: Although AMD may initially affect only one eye, it is ultimately a bilateral disease in most patients. The fellow eye typically develops AMD within 5 to 10 years of the first eye in patients with intermediate AMD.

---

Diagnosis

The diagnosis of AMD is established by a comprehensive ophthalmological examination performed by an experienced ophthalmologist. The examination must include:

Fundoscopy (Dilated Fundus Examination)

The cornerstone of AMD diagnosis is direct visualization of the retina after pharmacological pupillary dilation (mydriasis), typically achieved with topical mydriatic agents such as tropicamide or phenylephrine. Dilation is essential to allow adequate visualization of the macula and peripheral retina.

During the fundus examination, the ophthalmologist uses a slit lamp with a specialized fundus lens or a direct/indirect ophthalmoscope to inspect:

• The macula for drusen (number, size, and character), RPE changes (hyperpigmentation, depigmentation), geographic atrophy, subretinal fluid, subretinal hemorrhage, and disciform scarring
• The optic disc for signs of other pathology
• The peripheral retina for additional lesions

The clinical staging of AMD based on fundoscopic findings is guided by standardized grading systems such as the AREDS (Age-Related Eye Disease Study) classification:

• Stage 1 (No AMD): No drusen or only small drusen (<63 μm)
• Stage 2 (Early AMD): Multiple small drusen, or a few medium drusen, or pigment abnormalities
• Stage 3 (Intermediate AMD): Extensive medium drusen, or one or more large drusen (≥125 μm)
• Stage 4 (Advanced AMD): Neovascular AMD (wet AMD) in one or both eyes, or geographic atrophy involving the center of the macula in one or both eyes

Amsler Grid Testing

The Amsler grid is a simple, reproducible self-monitoring tool that patients can use at home. The patient covers one eye and focuses on the central dot of the grid with the uncovered eye. Wavy, distorted, blurry, or missing areas of the grid indicate macular pathology and should prompt urgent ophthalmic review.

Optical Coherence Tomography (OCT)

Optical Coherence Tomography (OCT) has revolutionized the diagnosis and management of AMD and is now arguably the most important single investigation in retinal practice. OCT uses near-infrared light interferometry to generate cross-sectional images of the retina with micrometer-level resolution, analogous to an in vivo optical biopsy of the retina.

OCT provides the following essential information in AMD:

• Visualization of individual retinal layers: Allowing precise identification and localization of pathological changes (drusen, RPE atrophy, subretinal fluid, intraretinal fluid, RPE detachment, CNV membrane)
• Detection and quantification of fluid: Critical for diagnosing wet AMD and monitoring response to anti-VEGF treatment
• Monitoring geographic atrophy progression in dry AMD
• Non-invasive and repeatable: Can be performed at every visit without discomfort or radiation exposure

OCT Angiography (OCTA) is an advanced variant that provides three-dimensional imaging of the retinal and choroidal vasculature without the need for intravenous contrast injection. This is increasingly important for the detection and characterization of CNV in wet AMD.

Fluorescein Angiography (FA)

Fluorescein angiography is an invasive imaging procedure in which sodium fluorescein dye is injected intravenously (typically into an arm vein). As the dye circulates through the retinal and choroidal vasculature, a specialized fundus camera with appropriate filters captures sequential images of the fluorescent dye flowing through the retinal circulation.

FA provides dynamic information about retinal vascular perfusion and is particularly valuable for:

• Detecting and characterizing CNV in wet AMD: identifying the type (classic or occult), location, and extent of the neovascular membrane
• Identifying retinal vascular leakage and pooling of fluorescein beneath the retina
• Determining treatment eligibility and target for laser photocoagulation or anti-VEGF injection
• Monitoring treatment response in wet AMD

FA is an essential investigation before initiating treatment for wet AMD but carries a small risk of allergic reaction to the fluorescein dye.

Indocyanine Green Angiography (ICGA)

Indocyanine Green Angiography (ICGA) uses indocyanine green (ICG) dye, which has different optical properties from fluorescein. The dye is injected intravenously to image the choroidal circulation, which is less well-visualized by standard fluorescein angiography.

ICGA is particularly indicated for:

• Serous or hemorrhagic RPE detachments: Where the fluorescein signal may be obscured by the detachment itself.
• Occult CNV: When fluorescein angiography fails to clearly delineate the neovascular lesion.
• Polypoidal choroidal vasculopathy (PCV): A variant of wet AMD that is particularly common in Asian populations. It is characterized by polyp-like dilations of the inner choroidal vasculature, which are best visualized with ICGA.
• Retinal angiomatous proliferation (RAP): Another wet AMD variant characterized by intraretinal neovascularization.

---

Treatment

Treatment of Dry (Atrophic) AMD

Dry AMD, particularly in its advanced geographic atrophy stage, represents one of the major unmet therapeutic challenges in ophthalmology. Until very recently, no proven treatment existed to halt or reverse geographic atrophy progression. However, the therapeutic landscape is changing:

• AREDS2 Nutritional Supplementation: The landmark Age-Related Eye Disease Study (AREDS) and its follow-up (AREDS2) established that a specific combination of high-dose nutritional supplements significantly reduces the risk of progression from intermediate AMD or advanced AMD in one eye to advanced AMD:

  • Vitamin C (500 mg/day)
  • Vitamin E (400 IU/day)
  • Zinc (80 mg/day as zinc oxide)
  • Copper (2 mg/day as cupric oxide, added to prevent zinc-induced copper deficiency)
  • Lutein (10 mg/day) and Zeaxanthin (2 mg/day) replaced beta-carotene in the AREDS2 formula because beta-carotene was found to increase lung cancer risk in smokers.

  The AREDS2 formula reduced the risk of progression to advanced AMD by approximately 25% over 5 years in high-risk patients (those with intermediate AMD or advanced AMD in one eye). It does not restore lost vision but can slow the progression of disease in appropriate patients.

• Emerging Treatments for Geographic Atrophy: In 2023, the FDA approved pegcetaplan alfa (Syfovre) and avacincaptad pegol (Izervay), the first pharmacological treatments specifically approved for geographic atrophy secondary to dry AMD. Both are complement pathway inhibitors (targeting C3 and C5 respectively) administered by intravitreal injection and have demonstrated modest but statistically significant reductions in the rate of geographic atrophy expansion in clinical trials.

Treatment of Wet (Neovascular) AMD: Anti-VEGF Therapy

The introduction of anti-VEGF (anti-Vascular Endothelial Growth Factor) therapy represents the most transformative advance in the treatment of retinal disease in recent decades. It fundamentally changed the natural history of wet AMD from one of inevitable severe vision loss to one of largely effective disease control with preservation, and sometimes even improvement, of vision.

The Rationale for Anti-VEGF Therapy

VEGF is the key molecular driver of pathological angiogenesis (neovascularization) in wet AMD. It promotes the proliferation, migration, and increased permeability of vascular endothelial cells, stimulating the formation of the abnormal, leaky CNV membrane. By blocking VEGF, either by neutralizing the circulating protein or by blocking its receptor, anti-VEGF drugs suppress CNV growth, reduce vascular permeability, decrease subretinal and intraretinal fluid accumulation, and allow the retina to recover structural integrity.

Available Anti-VEGF Agents

Several anti-VEGF agents are approved or widely used for the treatment of neovascular AMD:

• Ranibizumab (Lucentis): A humanized monoclonal antibody Fab fragment that binds and neutralizes all isoforms of VEGF-A. The first anti-VEGF agent specifically developed and approved for intravitreal injection in AMD. Demonstrated landmark efficacy in the MARINA and ANCHOR trials.

• Bevacizumab (Avastin): A full-length humanized monoclonal antibody that binds VEGF-A. Originally developed as a systemic anti-cancer agent, bevacizumab has been used off-label for intravitreal injection in AMD with demonstrated efficacy comparable to ranibizumab (established by the CATT and IVAN trials) at substantially lower cost.

• Aflibercept (Eylea): A recombinant fusion protein combining the ligand-binding domains of VEGF receptors 1 and 2 with the Fc portion of IgG1. Binds VEGF-A, VEGF-B, and placental growth factor (PlGF) with high affinity. May be administered less frequently than ranibizumab or bevacizumab in some patients.

• Brolucizumab (Beovu): A humanized single-chain antibody fragment with high potency and long durability, allowing quarterly or biannual dosing in some patients. Associated with a small but significant risk of intraocular inflammation and retinal vasculitis requiring careful monitoring.

• Faricimab (Vabysmo): A bispecific antibody that simultaneously inhibits both VEGF-A and Ang-2 (angiopoietin-2), addressing two pathways involved in CNV. Designed to allow extended treatment intervals (up to every 4 months) in responders.

Treatment Administration

All anti-VEGF agents for AMD are administered as intravitreal injections, which are injected directly into the vitreous cavity of the eye by an ophthalmologist in a sterile procedure room. The injection is performed under local anesthesia (topical or subconjunctival) and is generally well-tolerated with minimal discomfort. The procedure takes only a few minutes.

Treatment protocols vary by agent and are individualized to each patient’s clinical response:

• Fixed dosing (monthly): The most intensive protocol, providing maximum efficacy but high treatment burden (12 injections per year)
• Treat-and-extend (TAE): The most commonly used protocol in clinical practice; treatment intervals are progressively extended in 2-week increments in patients with stable, dry retinas. This reduces treatment burden while maintaining efficacy. Intervals are shortened in response to signs of disease activity.
• Pro re nata (PRN, as needed): Monthly monitoring with treatment only when disease activity is detected. This requires reliable patient attendance at monitoring visits.

With appropriate anti-VEGF treatment, the majority of patients with wet AMD achieve stabilization of vision, and approximately 30–40% experience meaningful visual improvement. This represents a dramatic improvement over the natural history of untreated wet AMD, in which the majority of patients lose two or more lines of visual acuity within two years.

Laser Photocoagulation

Conventional laser photocoagulation uses a high-energy laser beam to thermally destroy the CNV membrane, including the overlying retinal tissue. While effective at ablating CNV, it inevitably destroys the overlying photoreceptors and creates a permanent scotoma, a permanent blind spot in the treated area. For this reason, laser photocoagulation is now reserved for the rare subtype of classic, extrafoveal CNV where the neovascular membrane does not involve the foveal center, and is almost never used as monotherapy in patients with subfoveal or juxtafoveal CNV. It may occasionally be used as an adjunct to anti-VEGF therapy in selected cases.

Photodynamic Therapy (PDT)

Photodynamic therapy (PDT) with verteporfin (Visudyne) is a selective, non-thermal laser treatment in which:

1. Verteporfin, a photosensitizing dye, is administered intravenously.
2. The dye selectively accumulates in the abnormal, proliferating CNV endothelium.
3. A non-thermal diode laser (wavelength 689 nm) is applied to the macula, activating the verteporfin and generating reactive oxygen species that selectively damage and occlude the CNV vasculature without destroying overlying retinal tissue.

PDT is now used primarily in combination with anti-VEGF therapy for specific wet AMD variants, particularly polypoidal choroidal vasculopathy (PCV), where it has demonstrated superior outcomes compared to anti-VEGF monotherapy. As monotherapy, PDT has been largely superseded by anti-VEGF treatment.

---

Prevention

While AMD cannot be completely prevented, particularly in individuals with strong genetic predisposition, there is substantial evidence that modifying risk factors and adopting protective lifestyle behaviors can meaningfully delay disease onset and slow progression:

1. Quit Smoking

This is the single most impactful modifiable step any patient can take to reduce their AMD risk. Current smokers have two to four times the AMD risk of non-smokers. Stopping smoking at any age reduces this risk, and the benefit increases with each smoke-free year.

2. Avoid Alcohol Abuse

Heavy alcohol consumption should be avoided. Moderate consumption may be tolerable, but abstinence from heavy or binge drinking reduces oxidative stress and systemic vascular risk.

3. Adopt a Macula-Protective Diet

Nutritional choices play an important role in macular health:

• Leafy green vegetables (spinach, kale, Swiss chard): Rich in lutein and zeaxanthin, the carotenoid pigments that constitute the macular pigment and absorb damaging short-wavelength blue light reaching the photoreceptors. High dietary intake of lutein and zeaxanthin is associated with significantly lower AMD risk.
• Colorful fruits and vegetables (peppers, corn, citrus fruits, berries): Provide antioxidant vitamins C and E, carotenoids, and polyphenols.
• Oily fish (salmon, mackerel, sardines, herring): Rich in long-chain omega-3 fatty acids (DHA and EPA), which are essential structural components of photoreceptor outer segment membranes and have anti-inflammatory properties. High fish intake is associated with reduced AMD risk.
• Nuts and seeds: Sources of vitamin E and zinc.
• Whole grains and legumes: Lower glycemic index foods are associated with reduced AMD risk. High-glycemic diets may promote oxidative stress in the retina.

4. Maintain a Healthy Body Weight

Achieving and maintaining a healthy BMI reduces the association with obesity-related inflammatory and metabolic pathways that contribute to AMD risk. For overweight and obese individuals, weight loss is an important preventive measure.

5. Control Blood Pressure, Diabetes, and Cardiovascular Risk Factors

Optimal management of hypertension, diabetes, and dyslipidemia through medication, diet, and lifestyle modification protects the choroidal and retinal microcirculation from the cumulative damage that predisposes to AMD.

6. Protect Eyes from Ultraviolet and High-Energy Light

Wearing high-quality sunglasses that provide 100% UV protection (blocking both UVA and UVB radiation) whenever outdoors in sunlight reduces cumulative photochemical damage to the RPE. Sunglasses that also filter short-wavelength blue light may provide additional protection. Wide-brimmed hats provide complementary sun protection.

7. Regular Eye Examinations

Annual or biennial comprehensive eye examinations by an ophthalmologist, including dilated fundus examination, are strongly recommended for all adults over 50, especially for those with:

• A family history of AMD
• Known risk factors (smoking, hypertension, diabetes)
• Symptoms suggestive of macular disease

Early detection of AMD, before significant vision loss has occurred, allows timely initiation of AREDS2 supplementation and close monitoring for conversion to wet AMD. At that point, prompt anti-VEGF treatment can preserve vision that would otherwise be irreversibly lost.

8. Home Amsler Grid Monitoring

Patients with known intermediate or advanced AMD in one eye should be instructed in the use of the Amsler grid for regular home monitoring of their vision. Any sudden development of new distortion or scotoma should prompt urgent ophthalmological review within 24–48 hours, as it may signal conversion from dry to wet AMD. This is a treatable emergency where early treatment dramatically improves visual outcomes.

---

Sources and Bibliography

• MSD Manual (Professional Edition) Age-Related Macular Degeneration (AMD)

• Orphanet: Age-Related Macular Degeneration

• Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clinical Interventions in Aging. 2017 Aug 22;12:1313-1330. doi: 10.2147/CIA.S143508. PubMed

• Bae K, Kim HJ, Shin YK, Kang SW. Predictors of neovascular activity during neovascular age-related macular degeneration treatment based on optical coherence tomography angiography. Scientific Reports. 2019 Dec 17;9(1):19240. doi: 10.1038/s41598-019-55871-8. PMC

• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355(14):1419-1431.

• Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005-2015.

• Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nature Reviews Disease Primers. 2021;7(1):31.

• Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738.

• Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA. 1994;272(18):1413-1420.

• Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5):1079-1091.